Background {#Sec1}
==========

Reactions to the same drug differ significantly among individuals. Thus, analyzing a drug's safety and efficacy is complicated, causing difficulties in finding new treatments for major diseases. Inherited differences in individual drug-metabolizing enzymes are typically monogenic traits, and their influence on the pharmacokinetics and pharmacologic effects of medications are determined by the importance of the polymorphic enzymes for the activation or inactivation of drug substrates \[[@CR1]\]. Pharmacogenetics and pharmacogenomics deal with possible associations of a single genetic polymorphism or multiple gene profiles and responses to drugs \[[@CR2]\]. The goal of pharmacogenetic research is to provide information for a patient with the right medicine at the right dose for optimal treatment outcomes. The majority of pharmacogenomic studies have focused on candidate genes thought to be involved in the pharmacokinetics or mechanism of drug action \[[@CR3], [@CR4]\].

Recent studies have shown that certain genes have close relationships with the outcomes of drug therapy and that different genotypes may determine how the patient responds to a drug. These gene variants are called very important pharmacogenetic (VIP) variants \[[@CR5]\], and are listed in the Pharmacogenomics Knowledge Base (PharmGKB: <http://www.pharmgkb.org>). In total, there are 126 VIP variants that occur in 44 different genes and variously code for cytochrome P450 oxidases, drug targets, drug receptors, and drug transporters.

Individual responses to medications vary significantly among different populations, and great progress in understanding the molecular basis of drug actions has been made in the past 50 years. The field of pharmacogenomics seeks to elucidate inherited differences in drug disposition and effects. While we know that different populations and ethnic groups are genetically heterogeneous, we have not found any pharmacogenomics information regarding minority groups, such as the Uygur ethnic group in northwest China.

The Uygur is an ethnic group primarily located in the Xinjiang Uygur Autonomous Region of China. The Uygur is one of China's largest ethnic groups, with a long history in the region and distinct culture and traditions. They were originally a nomadic Turkish people in north and northwestern China. The Uygur language is a Turkic language very similar to Turkish.

In this study, we aimed to identify the allele frequencies of VIP variants in the Uygur and to determine the difference in allele frequencies between the Uygur and 11 populations from the HapMap data set. The results of this study will extend our understanding of ethnic diversity and pharmacogenomics, and enable medical professionals to use genomic and molecular data to effectively implement personalized medicine in the future.

Materials and methods {#Sec2}
=====================

Study participants {#Sec3}
------------------

We recruited a random sample of unrelated Uygur adults from the Xinjiang Region of China. The subjects selected were judged to be of good health and had exclusively Uygur ancestry for at least the last three generations. Thus, the subjects were thought to be representative samples of the Uygur population with regard to ancestry and environmental exposures. Blood samples were taken according to the study protocol, which was approved by the Clinical Research Ethics of Northwest University, Tibet University for Nationalities, Xinjiang Medical University, and the people's hospital of Xinjiang Uygur Autonomous Region. Signed informed consent was also obtained from each participant enrolled in the study. Based on the abovementioned inclusion criteria, 96 randomly-selected, healthy, unrelated Uygur individuals were recruited from the Xinjiang Province.

Variant selection and genotyping {#Sec4}
--------------------------------

We selected genetic variants from published polymorphisms associated with VIP variants from the PharmGKB database. We designed assays for the 85 genetically-variant loci in 37 genes that formed the basis for our our analyses. We excluded loci if we could not design an assay. We extracted genomic DNA from peripheral blood obtained from the subjects using the GoldMag-Mini Whole Blood Genomic DNA Purification Kit (GoldMagLtd. Xi'an, China) according to the manufacturer's protocol. The DNA concentration was measured with a NanoDrop 2000C spectrophotometer (Thermo Scientific, Waltham, MA, USA). The Sequenom MassARRAY Assay Design 3.0 software (San Diego, CA, USA) was used to design multiplexed single nucleotide polymorphism (SNP) MassEXTEND assays \[[@CR6]\]. SNP genotyping analysis was performed using the standard protocol recommended by the manufacturer with a Sequenom MassARRAY RS1000. Sequenom Typer 4.0 software was used to manage and analyze the SNP genotyping data as described in a previous report \[[@CR7]\].

HapMap genotype data {#Sec5}
--------------------

The genotype data of individuals from eleven populations were downloaded from the International HapMap Project web site (HapMap_release127) at <http://hapmap.ncbi.nlm.nih.gov/biomart/martview/e4f42d4d0acde5ea6c35312381c1e461>. The eleven populations included those of (1) African ancestry in Southwest USA (ASW); (2) Utah, USA residents with Northern and Western European ancestry from the CEPH collection (CEU); (3) Han Chinese in Beijing, China (CHB); (4) Chinese in metropolitan Denver, CO, USA (CHD); (5) Gujarati Indians in Houston, Texas, USA (GIH); (6) Japanese in Tokyo, Japan (JPT); (7) Luhya in Webuye, Kenya (LWK); (8) Mexican ancestry in Los Angeles, California, USA (MEX); (9) Maasai in Kinyawa, Kenya (MKK); (10) Toscani in Italy (TSI); and (11) Yoruba in Ibadan, Nigeria (YRI).

Statistical analyses {#Sec6}
--------------------

We used Microsoft Excel and SPSS 17.0 statistical packages (SPSS, Chicago, IL, USA) to perform Hardy--Weinberg Equilibrium (HWE) analysis and the *χ*^2^ test. The validity of the frequency of each VIP variant in the Uygur data was tested by assessing the departure from HWE using an exact test. We calculated and compared the genotype frequencies of the variants in the Uygur data with those in the eleven populations separately using the *χ*^2^ test. All *p* values obtained in this study were two-sided, and Bonferroni's adjustment for multiple tests was applied to the level of significance, which was set at *p* \< 0.05/(85\*11). The purpose of the *χ*^2^ test was to discover sites with significant differences. Afterwards, we obtained the SNP allele frequencies from the ALleleFREquency Database (<http://alfred.med.yale.edu>), and analyzed the global patterns of genetic variation at specific loci.

Analysis of population genetic structures {#Sec7}
-----------------------------------------

Some studies point out that population genetic structure is central to the study of human origins, DNA forensics, and complex diseases \[[@CR8]\]. We believe it is also important for pharmacogenomics. Fst and structure analyses are common in population genetic studies. Because of the insights that F-statistics can provide about the processes of differentiation among populations, over the past 50 years they have become the most widely used descriptive statistics in population and evolutionary genetics \[[@CR9]\]. Wright's F-statistics describe the level of heterozygosity in each level of a hierarchically-subdivided population. More specifically, F-statistics relate the departure from panmixia in the total population and within subpopulations to the total homozygosity. The most commonly reported statistic, Fst, measures the differentiation of a subpopulation relative to the total population, and is directly related to the variance in allele frequency between subpopulations. To further investigate variation at the VIP locus in terms of population structure, we used the model-based clustering method implemented in Structure (<http://pritchardlab.stanford.edu/structure.html>).

We used the Arlequin ver 3.1 software to calculate the value of Fst to infer the pairwise distance between populations. Pairwise Fst values were calculated on the primary, 84 SNP dataset in Arlequin3.5 \[[@CR10]\] using Reynolds' distance \[[@CR11]\] with significance tested using 100 permutations. To further investigate population structure, we used the model-based clustering method implemented in Structure ver. 2.3.1. Fst is directly related to the variance in allele frequency among populations and to the degree of resemblance among individuals within populations. If Fst is small, it means that the allele frequencies within each population are similar; if it is large, it means that the allele frequencies are different.

To analyze the genetic structure, the Bayesian clustering algorithm-based program Structure ver. 2.3.1 was used to assign the samples within a hypothetical K number of populations as proposed by Pritchard et al. \[[@CR12]\]. Analyses were performed using the ancestry model with correlated allele frequencies in eleven independent runs from K = 2 to K = 7. The MCMC analyses for each structure analysis (from K = 2 to K = 7) was run for 10,000 steps after an initial burn-in period of 10,000 steps. To assess the most likely number of clusters, we calculated △K following Evanno et al. \[[@CR13]\]. When the software ran to completion and results were obtained, we constructed bar charts summarizing the results using drawing software.

Results {#Sec8}
=======

Basic information about the selected VIP loci in Uygur is listed in Table [1](#Tab1){ref-type="table"}. The 85 VIP loci relate to 37 genes that belong to the cytochrome P450 superfamily, the nuclear receptor family, the G-protein coupled receptor family, the alcohol dehydrogenase family, the adrenergic receptors family, the ATP-binding cassette (ABC) transporters superfamily, and the eag family.Table 1Basic characteristic of selected variants and allele frequencies in the Uygur populationSNP IDGenesFamilyPhaseAllele AAllele BAllele AAllele BAmino Acid TranslationFunctionrs1801131MTHFRmethylenetetrahydrofolate reductase familyPhase ICA0.2920.708Glu429AlaMissensers1801133MTHFRmethylenetetrahydrofolate reductase familyPhase ITC0.3490.651Ala222ValMissensers890293CYP2J2cytochrome P450 superfamilyPhase IGT0.50.5-5′ Flankingrs3918290DPYD-PhaseIGA10-Donorrs6025F5-OthersGA0.9790.021Arg534GlnMissensers20417PTGS2-Phase IGC0.990.01-5′ Flankingrs689466PTGS2-Phase IAG0.7210.279-5′ Flankingrs4124874UGT1A1UDP-glucuronosyltransferase familyPhase IICA0.4740.526-5′ Flankingrs10929302UGT1A1UDP-glucuronosyltransferase familyPhase IIGA0.7630.237-5′ Flankingrs4148323UGT1A1UDP-glucuronosyltransferase familyPhase IIAG0.1250.875Gly71ArgIntronicrs7626962SCN5Asodium channel gene familyOthersGT10Ser1103TyrMissensers1805124SCN5Asodium channel gene familyOthersGA0.1930.807Pro1090LeuMissensers6791924SCN5Asodium channel gene familyOthersGA10Arg34CysMissensers3814055NR1I2nuclear receptor familyOthersCT0.6410.359-5′ Flankingrs2046934P2RY12G-protein coupled receptor familyOthersTC0.8390.161-Intronicrs1065776P2RY1G-protein coupled receptor familyOthersTC0.0730.927Ala19AlaSynonymousrs701265P2RY1G-protein coupled receptor familyOthersGA0.2190.781Val262ValSynonymousrs975833ADH1Aalcohol dehydrogenase familyPhase IGC0.6250.375-Intronicrs2066702ADH1Balcohol dehydrogenase familyPhase ICT10Arg370CysMissensers1229984ADH1Balcohol dehydrogenase familyPhase IGA0.6720.328His48ArgMissensers698ADH1Calcohol dehydrogenase familyPhase IAG0.8050.195Ile350ValMissensers17244841HMGCR-Phase IAT10-Intronicrs3846662HMGCR-Phase ITC0.4740.526-Intronicrs17238540HMGCR-Phase ITG10-Intronicrs1042713ADRB2adrenergic receptors familyPhase IGA0.4950.505Arg16GlyMissensers1042714ADRB2adrenergic receptors familyPhase IGC0.1530.847Gln27GluMissensers1800888ADRB2adrenergic receptors familyPhase ICT0.9740.026Thr164IleMissensers1142345TPMTmethyltransferase superfamilyPhase IIGA0.0050.995Tyr240CysMissensers1800460TPMTmethyltransferase superfamilyPhase IIAG0.0050.995Ala154ThrMissensers2066853AHR-OthersGA0.7840.216Arg554LysMissensers1045642ABCB1ATP-binding cassette (ABC) transporters superfamilyOthersTC0.5740.426Ile1145IleSynonymousrs2032582ABCB1ATP-binding cassette (ABC) transporters superfamilyOthersGT0.3820.618Ser893Ala Ser893ThrMissensers2032582ABCB1ATP-binding cassette (ABC) transporters superfamilyOthersGA0.8060.194rs2032582ABCB1ATP-binding cassette (ABC) transporters superfamilyOthersTA0.9080.092rs1128503ABCB1ATP-binding cassette (ABC) transporters superfamilyOthersTC0.6670.333Gly412GlySynonymousrs10264272CYP3A5cytochrome P450 superfamilyPhase ICT10Lys208LysNot Availablers776746CYP3A5cytochrome P450 superfamilyPhase IGA0.9840.016-Acceptorrs4986913CYP3A4cytochrome P450 superfamilyPhase ICT10Pro467SerMissensers4986910CYP3A4cytochrome P450 superfamilyPhase ITC10Met445ThrMissensers4986909CYP3A4cytochrome P450 superfamilyPhase ICT10Pro416LeuMissensers12721634CYP3A4cytochrome P450 superfamilyPhase ITC10Leu15ProMissensers2740574CYP3A4cytochrome P450 superfamilyPhase IAG0.9840.016-5′ Flankingrs3815459KCNH2eag familyOthersAG0.5640.436-Intronicrs36210421KCNH2eag familyOthersGT10Arg707LeuMissensers12720441KCNH2eag familyOthersCT10Arg444TrpMissensers3807375KCNH2eag familyOthersAG0.5210.479-Intronicrs4986893CYP2C19cytochrome P450 superfamilyPhase IGA0.9740.026Trp212nullStop Codonrs4244285CYP2C19cytochrome P450 superfamilyPhase IGA0.8280.172Pro227ProSynonymousrs1799853CYP2C9cytochrome P450 superfamilyPhase ICT10Arg144CysMissensers1801252ADRB1adrenergic receptors familyPhase IGA0.1670.833Ser49GlyMissensers1801253ADRB1adrenergic receptors familyPhase ICG0.8130.188Gly389ArgMissensers5219KCNJ11inward-rectifier potassium channel familyOthersCT0.6880.312Lys23GluIntronicrs1695GSTP1glutathione S-transferase familyPhase IIAG0.6830.317Ile105ValMissensers1138272GSTP1glutathione S-transferase familyPhase IITC0.0580.942Ala114ValMissensers1800497ANKK1Ser/Thr protein kinase familyPhase ITC0.2530.747Glu713LysMissensers6277DRD2G-protein coupled receptor familyOthersCT0.6560.344Pro290ProSynonymousrs4149056SLCO1B1solute carrier familyOthersTC0.8890.111Val174AlaMissensers7975232VDRnuclear receptor familyOthersCA0.6150.385-Intronicrs1544410VDRnuclear receptor familyOthersGA0.740.26-Intronicrs2239185VDRnuclear receptor familyOthersTC0.3950.605-Intronicrs1540339VDRnuclear receptor familyOthersGA0.50.5-Intronicrs2239179VDRnuclear receptor familyOthersAG0.620.38-Intronicrs3782905VDRnuclear receptor familyOthersCG0.7420.258-Intronicrs2228570VDRnuclear receptor familyOthersTC0.3160.684Met51Arg,Met51Lys,Met51ThrMissensers10735810VDRnuclear receptor familyOthersCT0.6880.313\--rs11568820VDRnuclear receptor familyOthersGA0.6580.342-Not Availablers1801030SULT1A1sulfotransferase familyPhase IIAG10Val223MetNot Availablers3760091SULT1A1sulfotransferase familyPhase IICG0.6590.341-5′ Flankingrs7294VKORC1-Phase IGA0.6950.305-3′ UTRrs9934438VKORC1-Phase IGA0.4270.573-Intronicrs28399454CYP2A6cytochrome P450 superfamilyPhase IGA10Val365MetMissensers28399444CYP2A6cytochrome P450 superfamilyPhase IAA-10Glu197Ser,Glu197ArgFrameshiftrs1801272CYP2A6cytochrome P450 superfamilyPhase ITA10Leu160HisMissensers28399433CYP2A6cytochrome P450 superfamilyPhase IGT0.130.87-5′ Flankingrs3745274CYP2B6cytochrome P450 superfamilyPhase IGT0.7920.208Gln172HisMissensers28399499CYP2B6cytochrome P450 superfamilyPhase ITC10Ile328ThrMissensers3211371CYP2B6cytochrome P450 superfamilyPhase ICT0.4950.505Arg487CysMissensers12659SLC19A1solute carrier familyOthersCT0.5890.411Pro192ProSynonymousrs1051266SLC19A1solute carrier familyOthersGA0.5790.421His27ArgMissensers1131596SLC19A1solute carrier familyOthersTC0.8720.128-5′ UTRrs4680COMT-Phase IIAG0.4320.568Val158Met5′ Flankingrs59421388CYP2D6cytochrome P450 superfamilyPhase ICT10Val287MetMissensers28371725CYP2D6cytochrome P450 superfamilyPhase IGA0.8960.104-Intronicrs16947CYP2D6cytochrome P450 superfamilyPhase IGA0.7260.274-Not Availablers61736512CYP2D6cytochrome P450 superfamilyPhase ICA/G/T10Val136MetIntronicrs28371706CYP2D6cytochrome P450 superfamilyPhase ICT10Thr107IleMissensers5030656CYP2D6cytochrome P450 superfamilyPhase IAAG-10-Non-synonymous

Using the *χ*^2^ test with the Bonferroni correction for multiple hypotheses and multiple comparisons, we found 0, 1, 3, 5, 7, 9, 10, 13, 16, 17, and 25 different loci in the frequency distributions when the Uygur population was compared to the TSI, MEX, GIH, CHD, CEU, CHB, ASW, JPT, MKK, LWK, and YRI populations, respectively. Three loci (rs776746, rs9934438, and rs7294) located in the *CYP3A5* and *VKORC1* genes were different in the Uygur population when compared with most of the populations (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}).Table 2Significant variants in Uygur compared to the 11 populations, as determined by Chi-square testSNP IDGenesChi-square test *p* valueCHBJPTCEUYRIASWCHDGIFLWKMEXMKKTSIrs1801131*MTHFR*2.64E-015.50E-025.61E-014.64E-051.28E-011.28E-011.23E-015.13E-023.21E-016.99E-014.68E-01rs1801133*MTHFR*5.56E-028.61E-016.49E-015.64E-096.93E-069.87E-016.81E-044.89E-084.45E-014.97E-117.77E-02rs6025*F5*\--5.47E-01\-\-\-\-\-\-\--rs20417*PTGS2*2.27E-303.82E-301.42E-303.59E-25\-\-\-\-\-\--rs689466*PTGS2*1.58E-049.82E-031.79E-028.07E-062.72E-033.17E-031.18E-024.71E-096.02E-016.96E-133.42E-02rs4124874*UGT1A1*5.43E-042.54E-028.95E-011.45E-186.07E-062.73E-021.58E-022.31E-146.95E-018.73E-145.94E-01rs10929302*UGT1A1*1.27E-021.55E-027.21E-012.68E-02\-\-\-\-\-\--rs4148323*UGT1A1*1.00E-028.23E-013.34E-043.34E-04-4.91E-011.52E-03-4.21E-02\--rs7626962*SCN5A*\-\--1.61E-03\-\-\-\-\-\--rs1805124*SCN5A*5.41E-021.67E-017.66E-013.09E-023.68E-017.42E-039.77E-011.04E-015.81E-011.01E-034.23E-01rs3814055*NR1I2*2.86E-011.37E-018.69E-011.21E-017.00E-017.20E-024.08E-012.75E-012.51E-018.66E-048.24E-01rs2046934*P2RY12*6.84E-016.10E-012.60E-012.50E-01\-\-\-\-\-\--rs701265*P2RY1*2.09E-015.56E-016.25E-012.75E-237.57E-114.26E-012.11E-014.41E-218.25E-011.87E-234.24E-01rs975833*ADH1A*7.76E-113.63E-092.56E-012.56E-01\-\-\-\-\-\--rs2066702*ADH1B*\-\--1.70E-142.43E-10\--7.05E-07\-\--rs1229984*ADH1B*4.84E-106.69E-091.28E-111.79E-11\-\-\-\-\-\--rs698*ADH1C*2.29E-044.26E-045.04E-081.35E-045.01E-023.58E-032.41E-013.71E-015.69E-014.18E-012.40E-02rs3846662*HMGCR*7.31E-019.72E-016.50E-021.61E-211.18E-086.07E-013.68E-028.13E-202.60E-022.51E-121.88E-01rs1042713*ADRB2*5.37E-012.62E-017.49E-032.31E-014.76E-013.59E-011.81E-015.87E-016.38E-016.13E-012.35E-03rs1042714*ADRB2*6.84E-017.77E-025.86E-083.04E-01\-\-\-\-\-\--rs1142345*TPMT*\-\--6.38E-02\-\--5.08E-054.66E-037.52E-52-rs2066853*AHR*6.40E-049.34E-065.30E-031.34E-052.98E-032.09E-032.84E-025.09E-071.08E-011.26E-033.22E-03rs1045642*ABCB1*8.23E-033.13E-023.10E-013.16E-187.87E-081.84E-049.12E-01-1.07E-014.28E-171.33E-01rs2032582*ABCB1*8.02E-013.09E-019.05E-03-1.06E-143.95E-02\-\-\-\--rs2032582*ABCB1*\-\-\--1.49E-011.77E-04\-\-\-\--rs2032582*ABCB1*\-\-\--1.23E-161.51E-10\-\-\-\--rs1128503*ABCB1*7.10E-012.93E-011.73E-051.63E-224.13E-127.84E-012.67E-011.51E-202.52E-035.63E-236.23E-05rs10264272*CYP3A5*\-\--1.76E-08\-\--3.72E-12-1.61E-07-rs776746*CYP3A5*4.82E-131.37E-125.51E-021.56E-439.11E-272.09E-101.04E-109.92E-383.17E-112.71E-281.52E-02rs3815459*KCNH2*4.49E-026.90E-04-2.69E-03\-\-\-\-\-\--rs3807375*KCNH2*9.10E-048.15E-088.52E-032.75E-071.82E-025.77E-041.94E-023.81E-076.07E-011.36E-052.76E-03rs4244285*CYP2C19*7.60E-037.79E-027.63E-018.20E-01\-\-\-\-\-\--rs1801252*ADRB1*3.99E-044.69E-04-1.77E-04\-\-\-\-\-\--rs1801253*ADRB1*4.01E-015.97E-014.11E-021.39E-04\-\-\-\-\-\--rs1695*GSTP1*1.97E-025.30E-064.87E-022.14E-015.59E-023.14E-025.37E-012.61E-041.46E-035.49E-015.90E-01rs1138272*GSTP1*\-\-\-\-\-\-\--3.82E-01\--rs1800497*ANKK1*5.75E-037.02E-034.03E-012.26E-033.61E-021.02E-039.04E-014.19E-027.81E-033.21E-025.35E-01rs6277*DRD2*7.51E-079.21E-072.73E-031.15E-09\-\-\-\-\-\--rs4149056*SLCO1B1*3.90E-012.55E-013.73E-01-3.47E-023.12E-01\-\--4.92E-011.43E-02rs7975232*VDR*3.64E-015.13E-012.26E-037.99E-063.56E-042.20E-017.13E-035.31E-095.87E-028.30E-097.35E-04rs1544410*VDR*7.55E-082.36E-036.90E-048.50E-012.39E-015.95E-083.45E-039.28E-019.17E-013.44E-026.49E-03rs2239185*VDR*2.76E-013.57E-01-4.96E-02\-\-\-\-\-\--rs1540339*VDR*4.18E-047.39E-052.87E-022.34E-082.07E-042.63E-051.43E-023.95E-112.23E-017.15E-112.40E-02rs2239179*VDR*1.49E-024.20E-033.05E-021.57E-011.22E-014.13E-037.35E-027.84E-012.95E-014.02E-017.32E-01rs3782905*VDR*3.53E-132.82E-171.09E-102.88E-14\-\-\-\-\-\--rs10735810*VDR*1.61E-011.87E-019.34E-021.81E-024.22E-024.66E-035.86E-011.58E-032.77E-031.90E-022.90E-01rs11568820*VDR*1.28E-018.00E-026.18E-031.16E-315.41E-088.53E-013.03E-013.47E-193.45E-026.79E-177.59E-02rs7294*VKORC1*4.64E-082.30E-053.77E-015.06E-052.06E-037.51E-071.38E-121.46E-027.81E-011.90E-043.15E-01rs9934438*VKORC1*3.05E-122.10E-094.69E-032.89E-261.19E-112.46E-114.83E-119.77E-191.61E-013.19E-169.26E-02rs1801272*CYP2A6*-1.08E-303.63E-34\-\-\-\-\-\-\--rs3745274*CYP2B6*3.21E-012.23E-011.95E-012.27E-052.73E-011.80E-016.90E-053.31E-022.34E-014.15E-041.30E-01rs28399499*CYP2B6*\-\--3.33E-064.73E-04\-\-\--1.80E-01-rs1051266*SLC19A1*8.64E-032.37E-034.08E-013.20E-092.10E-012.71E-014.03E-013.44E-103.83E-021.97E-144.33E-02rs4680*COMT*4.53E-028.67E-035.32E-011.75E-021.64E-022.29E-039.75E-015.38E-026.03E-013.36E-033.41E-01*p* \<0.05 indicates statistical significanceTable 3Number of variants significantly different from the 11 populations and corresponding gene families after correction for multiple testsGene FamilySignificant Variants (N)TSIMEXGIHCHDCEUCHBASWJPTMKKLWKYRImethylenetetrahydrofolate reductase family00000000222cytochrome P450 superfamily01121112224UDP-glucuronosyltransferase family00000010111sodium channel gene family00000000000nuclear receptor family00021211334G-protein coupled receptor family00000010110alcohol dehydrogenase family00002212012adrenergic receptors family00001000000methyltransferase superfamily00000010000ATP-binding cassette (ABC) transporters superfamily00001020212eag family00000001111inward-rectifier potassium channel family00000000000glutathione S-transferase family00000001000Ser/Thr protein kinase family00000000000G-protein coupled receptor family00000101002solute carrier family00000000011sulfotransferase family00000000100-00211324346Sum0135791012161725

For a global analysis, we combined our new data with previously published data, for a total of 66 population samples at rs776746 and rs7294. From Table [4](#Tab4){ref-type="table"} it can clearly be seen that the frequencies of the A allele of rs776746 were higher in Africa than in Asia and East Asia, but lower in Europe. For the East Asia data, frequencies ranged from 5 % to 50 %, and the frequencies were high in the She and Tujia population and lower in the Uygur and Tu populations. The frequencies of the A allele of rs7294 in East Asia ranged from 1 % to 35 %, and the frequency in the Uygur population was higher than in the other populations from East Asia.Table 4Allele frequencies of rs776746 and rs7294 in populations from different regions of the worldGeographic RegionPopulationCYP3A5rs776746VKORC1rs7294Allele A frequencyAllele G frequencyAllele A frequencyAllele G frequencyAfricaBantu speakers0.810.190.380.63Bantu speakers0.830.170.670.33San0.920.080.330.67Biaka0.940.060.810.19Mbuti0.930.070.830.17Yoruba0.940.060.500.50Mandenka0.690.310.560.44Mozabite0.150.850.270.73AsiaBedouin0.150.850.300.70Druze0.090.910.210.79Palestinian0.180.820.280.72Burusho0.220.780.620.38Kalash0.240.760.300.70Pashtun0.130.870.700.30Mongolian0.350.650.150.85Balochi0.200.800.520.48Balochi0.140.860.500.50Brahui0.120.880.480.52Hazara0.250.750.210.79Sindhi0.220.780.520.48Oroqen0.150.850.001.00East AsiaDai0.450.550.200.80Daur0.110.890.060.94Han0.260.740.010.99Hezhe0.170.830.170.83Japanese0.230.770.090.91Koreans0.190.820.050.95Lahu0.300.700.150.85Miao0.350.650.200.80Naxi0.220.780.110.89She0.450.550.250.75Tu0.100.900.100.90Tujia0.500.500.050.95Uyghur0.050.950.350.65Xibe0.220.220.170.83Yi0.200.800.150.85Cambodians, Khmer0.270.730.140.86EuropeAdygei0.120.880.150.85Basque0.040.960.280.72Estonian0.080.920.410.59French0.090.910.280.72Italians0.060.940.500.50Italians0.190.810.310.69Orcadian0.160.840.380.63Russians0.060.940.360.64Sardinian0.040.960.320.68North AmericaPima, Mexico0.540.460.480.52Maya, Yucatan0.300.700.640.36OceaniaPapuan New Guinean0.210.790.740.24Melanesian, Nasioi0.180.820.660.34SiberiaYakut0.100.900.060.94South AmericaAmerindians0.150.850.310.69Karitiana0.230.770.790.21Surui0.170.830.400.60

Pairwise Fst values were calculated for all population comparisons across loci. As shown in Table [5](#Tab5){ref-type="table"}, we found that pairwise Fst values for comparisons of the Uygur population with the other 11 populations ranged from 0.49686 to 0.581. Fst is directly related to the variance in allele frequency among populations and to the degree of resemblance among individuals within populations. If Fst is small, it means that the allele frequencies within each population are similar; if it is large, it means that the allele frequencies are different. The value of Fst for the Uygur and MEX populations was the smallest. We therefore conclude that the allele frequencies of the Uygur and MEX are similar. We speculate that the genetic backgrounds of the Uygur and MEX populations are similar.Table 5Fst values between population pairsUygurASWCEUCHBCHDGIHJPTLWKMEXMKKTSIYRIUygur0ASW0.532350CEU0.504180.156510CHB0.523770.203980.134820CHD0.527140.205930.12811−0.00090GIH0.503460.097250.036520.160880.156370JPT0.523820.186750.126830.003480.005210.149510LWK0.566940.020140.236240.282670.288190.174270.262570MEX0.496860.126320.026470.085440.07860.054640.084810.211350MKK0.540640.018170.157040.224750.228480.107140.200850.024680.153250TSI0.499870.153670.001830.114170.112440.041550.106940.235170.02620.157610YRI0.5810.018050.246120.285250.291910.174830.263110.004810.221530.025230.246470

We used a model-based clustering approach, as implemented in Structure, to infer population structure among the 12 populations. Different values ranging from 2 to 7 were assumed for K in Structure calculations. K = 3, 4, 5 were selected, based on the Estimated Ln Prob of Data and other recommendations of the Structure software manual. As shown in Fig. [1](#Fig1){ref-type="fig"}, when the K value was equal to 3, individuals were independently assigned to three affinity groups (subpopulations 1: Uygur, CEU, GIH, MEX, TSI; subpopulations 2: ASW, LWK, MKK, YRI; subpopulations 3: CHB, CHD, JPT) using the relative majority of likelihood to assign individuals to subpopulations. We tested additional values of K and obtained results suggesting that the genetic backgrounds of the Uygur and MEX populations are simila.Fig. 1Bayesian clustering of genotypic samples from 12 populations. Each vertical bar denotes an individual, whilst colors denote inferred clusters. Note that colors are not universal between k = 3 and 5

Discussion {#Sec9}
==========

The genotype frequencies of VIP variants differs among human populations. In this study, we genotyped the variants related to drug response in the Uygur ethnic group and compared the genotype frequencies with those in eleven populations. From the *χ*^2^ test, we found clear evidence that the allele characteristics of the *CYP3A5* rs776746 and *VKORC1* (rs9934438 and rs7294) variants in the Uygur population are quite different from that in other ethnic groups. We also found that the genetic backgrounds of the Uygur and MEX populations are similar, via Fst calculations and analysis of population structure.

*CYP3A5*, localized on chromosome 7q21-q22.1, encodes one of the CYP3A subfamily of enzymes \[[@CR14]\]. The most common nonfunctional variant of *CYP3A5* is designated as CYP3A5\*3. CYP3A5\*3 status is determined by the derived allele at rs776746, a change from A to G located in intron 3. This change creates a cryptic splice site that results in altered mRNA splicing, which may alter the reading frame and result in a premature termination codon and hence a nonfunctional protein \[[@CR14], [@CR15]\].

Individuals with CYP3A5\*1/\*1 and \*1/\*3 expresser genotypes metabolize some CYP3A substrates more rapidly than CYP3A5\*3/\*3 nonexpressers. One such substrate is tacrolimus, which is used to prevent post-transplantation organ rejection. CYP3A5\*1 carriers have a higher rate of tacrolimus clearance than those with the other genotypes, with \*1/\*1 individuals having a higher clearance than \*1/\*3 individuals, who have higher clearance than \*3/\*3 individuals \[[@CR16]\]. In ideal situations, the target tacrolimus concentration must be high enough to prevent transplant rejection \[[@CR17], [@CR18]\], but low enough to minimize toxicity \[[@CR19]\]. Tacrolimus trough concentrations are routinely monitored after transplantation, and the dose is appropriately adjusted.

Carbamazepine (CBZ), a first-line antiepileptic drug, has been widely prescribed for the treatment of partial and generalized tonic-clonic seizures. It has been reported that CYP3A5\*3 is associated with CBZ pharmacokinetics in Japanese \[[@CR20]\], Korean \[[@CR21]\], and Chinese \[[@CR22]\] epileptic patients, and that *CYP3A5* expressers are more likely to require higher CBZ maintenance doses than nonexpressers (GA + AA vs. GG). The *CYP3A5* genotype may also have dose-dependent effects on ABT-773 plasma levels. *CYP3A5* expressers have a higher rate of ifosfamide N-demethylation in the liver and kidney and of cyclosporine A metabolism in the kidney \[[@CR15]\].

CYP3A5\*3 is the most frequent and well-studied variant allele of *CYP3A5*. Its frequency varies widely across human populations. In white populations, the estimated allele G frequency of CYP3A5\*3 is 0.82--0.95, in African American is 0.33, in Japanese is 0.85, in Chinese is 0.65, in Mexicans is 0.75, in Pacific Islanders is 0.65, and in Southwest American Indians is 0.4 \[[@CR15]\]. In our study, the frequency of allele G is higher than in other population from China. This suggests that ancestry should be considered when determining dosages for different patients.

The *VKORC1* (vitamin K epoxide reductase complex, subunit 1) gene, which encodes vitamin K epoxide reductase complex subunit 1, located on chromosome 16, includes three exons \[[@CR23]\]. The 1173C \> T (rs9934438) transition in intron 1 and the 3730G \> A (rs7294) transition in the 3ʹ untranslated region (UTR), are two common polymorphisms \[[@CR24]\].

Several authors have shown that acenocoumarol dose is also influenced by *VKORC1* genotype. Reitsma et al. showed in 2005 that Dutch patients carrying one or two variant alleles for the 1173 polymorphism required a 28 % and 47 % lower dose, respectively, when compared with wild types \[[@CR25]\]. In Greek acenocoumarol users, heterozygous carriers of a variant allele required a 19 % lower dose and homozygous carriers a 63 % lower dose \[[@CR26]\]. Similar percentages were found in a German and Austrian population (25 % and 52 %) \[[@CR27]\], in a Serbian population (27 % and 62 %) \[[@CR28]\], and amongst Lebanese acenocoumarol users (34 % and 50 %) \[[@CR29]\]. Reitsma et al. also investigated the influence of *VKORC1* polymorphism on phenprocoumon dose requirements. Patients with a CT genotype at position 1173 had a 10 % lower dose and patients with a TT genotype a 52 % lower dose than wild types (CC) \[[@CR25]\]. This effect was also seen in several German and Austrian studies. The dose in phenprocoumon users with one variant *VKORC1* allele was 19--31 % lower than in wild type users, and 43--51 % lower in users with two variant alleles \[[@CR27]\].

Warfarin is a commonly prescribed oral anticoagulant, used to prevent thromboembolic diseases in patients with deep vein thrombosis, atrial fibrillation, recurrent stroke, or heart valve prosthesis \[[@CR30]\]. Some studies have suggested that carriers of the 1173TT genotype require a dose of warfarin significantly lower than that of carriers with the CC or CT genotypes \[[@CR24]\]. On the other hand, the 3730G \> A polymorphism was associated with differences in the average dose of warfarin prescribed, with patients carrying the GG genotype being prescribed a significantly lower average daily dose of warfarin \[[@CR24], [@CR31]\].

In summary, *VKORC1* polymorphisms can significantly alter warfarin pharmacodynamics and maintenance dose requirements. Patients with the 1173T (rs9934438) allele require a lower warfarin dose compared with 35 mg/week for the wild-type carriers \[[@CR32]\]. Patients with 3730A (rs7294) need a higher warfarin dose \[[@CR32], [@CR33]\]. In our study, the frequency of carriers of the allele T of rs9934438 and allele G of rs7294 are lower than in other Asian populations, and higher than in European and YRI populations, which suggests that the optimal dosage of warfarin should be decided based on the specific genotype in individual Uygur patients.

Conclusion {#Sec10}
==========

The genotype frequencies of VIP variants affect a populations' response to drugs to a great extent. Determination of the genotype distribution and frequencies of VIP variants in a population is necessary to provide a theoretical basis for safer drug administration and an improved curative effect. Our results complement the currently available data on the Uygur ethnic group in the pharmacogenomics database, and furthermore, provide a basis for safer and more effective drug administration in the Uygur. However, our sample size of Uygur is relatively small, and further investigation in a larger cohort of Uygur is necessary to ascertain the generalizability and extrapolation of our results to these and other conditions in the Uygur population.

VIP variants

:   very important pharmacogenetic variants

SNP

:   single nucleotide polymorphism

ASW

:   African ancestry in Southwest USA

CEU

:   Utah residents with Northern and Western European ancestry from the CEPH collection

CHB

:   Han Chinese in Beijing, China

CHD

:   Chinese in Metropolitan Denver, Colorado

GIH

:   Gujarati Indians in Houston, Texas

JPT

:   Japanese in Tokyo, Japan

LWK

:   Luhya in Webuye, Kenya

MEX

:   Mexican ancestry in Los Angeles, California

MKK

:   Maasai in Kinyawa, Kenya

TSI

:   Toscans in Italy

YRI

:   Yoruba in Ibadan, Nigeria (West Africa)
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